Why Cortexyme Stock Imploded in 2021
The clinical-stage drugmaker's shares imploded last year in response to the failure of its lead Alzheimer's disease candidate atuzaginstat in a combined phase 2/3 study. Specifically, atuzaginstat reportedly missed both of its co-primary endpoints in the phase 2/3 Gain trial as a treatment for mild to moderate forms of Alzheimer's disease. Since announcing these disappointing trial results late last year, Cortexyme has said that it plans to trial the drug yet again.